Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LESLIE BRYAN FORGOSH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154305738
CMS profile
278624
Location
SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$37.62

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $37.62 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $22.67 1
Amgen Inc. $14.95 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LESLIE BRYAN FORGOSH

NPI 1154305738 · CMS profile ID 278624

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $37.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $22.6712/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662643119 CMS
Amgen Inc. $14.9502/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662637654 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.62 2
PY2020 $13.55 1
PY2022 $3,264.08 18
PY2023 $2,534.72 16
PY2024 $1,618.47 10
PY2025 $1,013.54 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,031.09 11
PY2025 Principal investigator $1,145,528.44 27
PY2024 Principal investigator $1,362,432.04 31
PY2023 Recipient $140.82 1
PY2023 Principal investigator $1,104,464.55 33
PY2022 Recipient $3,197.00 1
PY2022 Principal investigator $739,768.96 53
PY2021 Recipient $4,441.01 1
PY2021 Principal investigator $667,326.41 59
PY2020 Recipient $6,717.97 2
PY2020 Principal investigator $475,435.63 71
PY2019 Principal investigator $661,892.22 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,046.00 12/23/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1107217002
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $8,205.00 11/07/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1107217004
Principal investigator 1 Amgen Inc. $29,398.00 10/25/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF MINNESOTA MEDICAL CTR
OCEANa-Outcomes P3 CV No dispute reported 06/30/2026 1096311795
Principal investigator 1 Novartis Pharmaceuticals Corporation $126,675.75 09/03/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1089691739
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,447.00 08/29/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Participant and Investigator Blinded, Sponsor Open-label, Placebo-controlled, Single Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) No dispute reported 06/30/2026 1089695701
Principal investigator 1 Novartis Pharmaceuticals Corporation $106.92 08/27/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1089688729
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,282.00 08/26/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1085983214
Principal investigator 1 Amgen Inc. $35,473.00 08/10/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF MINNESOTA MEDICAL CTR
OCEANa-Outcomes P3 CV No dispute reported 06/30/2026 1096311789
Principal investigator 1 Amgen Inc. $660.03 07/25/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF MINNESOTA MEDICAL CTR
OCEANa-Outcomes P3 CV No dispute reported 06/30/2026 1096311791
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,582.96 07/25/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089688701
Principal investigator 1 Novartis Pharmaceuticals Corporation $102.60 07/24/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1089689093
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,350.00 06/27/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1085983038
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,632.00 05/28/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1085982710
Principal investigator 1 Novartis Pharmaceuticals Corporation $160,725.00 05/09/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089695405
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,950.00 04/26/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1089696091
Principal investigator 1 Amgen Inc. $11,862.00 04/19/2024 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20170625_VESALIUS - CV No dispute reported 06/30/2026 1096306879
Principal investigator 1 Amgen Inc. $268,867.00 04/19/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF MINNESOTA MEDICAL CTR
OCEANa-Outcomes P3 CV No dispute reported 06/30/2026 1096311793
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,512.00 04/11/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1085983208
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,166.15 02/22/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1089695567
Principal investigator 1 Eli Lilly and Company $2,943.39 01/31/2024 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1137360039
Principal investigator 1 Amgen Inc. $16,351.03 01/25/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF MINNESOTA MEDICAL CTR
OCEANa-Outcomes P3 CV No dispute reported 06/30/2026 1096311797
Principal investigator 1 Eli Lilly and Company $491.22 01/25/2024 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF MINNESOTA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137365073
Principal investigator 1 Novartis Pharmaceuticals Corporation $129,610.42 01/25/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089688605
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,299.00 01/23/2024 Non-covered Recipient Entity
Fairview Health Services
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1085983036
Principal investigator 1 Amgen Inc. $40,768.00 01/16/2024 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20170625_VESALIUS - CV No dispute reported 06/30/2026 1096306881
Principal investigator 1 Novartis Pharmaceuticals Corporation $401.72 01/15/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1089688807
Principal investigator 1 Janssen Research & Development, LLC $13,650.00 01/12/2024 Non-covered Recipient Entity
Fairview Hlth Svcs
70033093ACS3003 No dispute reported 06/30/2026 1078968765
Principal investigator 1 Eli Lilly and Company $127,752.00 01/09/2024 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1137360037
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,974.56 01/09/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1089688961
Principal investigator 1 Eli Lilly and Company $57,897.00 01/02/2024 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137359183
Principal investigator 1 Novartis Pharmaceuticals Corporation $186,250.29 01/02/2024 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1089691351